Published in:
Open Access
01-12-2015 | Oral presentation
O034. Type of pain and onabotulinumtoxin-A in chronic migraine: four years of follow-up
Authors:
Chiara Cesaretti, Elisabetta Molesti, Francesco Lolli, Aldo Amantini, Silvia Lori
Published in:
The Journal of Headache and Pain
|
Special Issue 1/2015
Login to get access
Excerpt
Refractory chronic migraine (rCM)[
1] is a debilitating neurological disorder, characterized by headache on ≥ 15 days per month for > 3 months, resistant to conventional symptomatic and/or prophylactic polytherapy. The effectiveness of the OnabotulinumtoxinA (OnabotA) was demonstrated in PREEMPT trials and approved in 2010 for CM treatment[
2,
3]. The prophylactic pharmacological actions of OnabotA include: a direct antinociceptive-analgesic effect for primary peripheral afferent terminals by inhibiting release of nociceptive mediators (glutamate, substance P, CGRP)[
4] and an indirect effect presumed to involve inhibition of peripheral and central sensitization in trigeminovascular neurons. The purpose of this study was to evaluate the efficacy, safety and tolerability of OnabotA as a prophylactic therapy in patients with rCM and observe the influence of the type of pain on the effectiveness of the treatment itself. …